CHEMICAL/BIOLOGICAL DEFENSE (EMD)

Abstract

This program element (PE) resources System Development & Demonstration across the Enabling Investments, Mitigate, Protect, and Understand portfolios. CBDP investments provide an integrated, layered capability to enable CWMD missions ranging from combat operations to DoD support to domestic incident prevention and response. The projects in this PE support the development, build, and test of products to verify that all operational and derived requirements have been met, and to support production or deployment decisions. The activities include mature system development, integration, and demonstration to support Milestone C decisions, and conducting operational test and evaluation of production representative articles. FY23 funding accelerates characterization and situational awareness of emerging biothreats and accelerates delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines. Individual Projects include: - Enabling Investments (EN5): Provides fundamental knowledge, and technology demonstrations as key portfolio enablers integral to responding to emerging threats. Dedicated funding in this Project supports National and Departmental incident response and preparedness regarding CB threats. - Mitigate (MT5): Preserves combat power by mitigating exposure to CB hazards and restoring combat readiness of critical personnel and platforms. Enables Joint Force lethality by providing capabilities for Warfighters to rapidly respond to and mitigate the adverse effects of CB hazards. Fields mitigation capabilities against engineered biological agents, opioids and other Pharmaceutical-Based Agents, and Fourth Generation Agents (FGAs). - Protect (PT5): Provides the Joint Force the ability to prevent the effects from exposure to chemical and biological hazards. Protects personnel against chemical, biological, and radiological (CBR) liquid, vapor, and aerosol hazards through next-generation prototypes of masks, filters, and ensembles to reduce physiological, psychological and logistical burdens to the Warfighter. Medical countermeasure efforts conducted during this phase include the development of a large scale manufacturing process and validation of that process, nonclinical studies, demonstration of manufacturing consistency, and expanded clinical human safety studies. Focuses on platform based approaches to accelerate development of prophylactic medical countermeasures that rapidly and durably protect against BWAs, toxins, non-traditional and emerging chemical threats with minimal doses. The results of these efforts will be used to submit a Biologics License Application (BLA) to the FDA for product licensure. - Understand (UN5): Provides the Joint Force the ability to detect and identify hazards from traditional and emerging chemical and biological threats to improve the timeliness and confidence of information for decision makers. Supports freedom of maneuver and informs commanders' decisions by predicting, locating, identifying, analyzing, and warning of CB hazards. - Contamination Avoidance (CA5), Collective Protection (CO5), Decontamination (DE5), Individual Protection (IP5), Information Systems (IS5), Medical Biological Defense (MB5) and Medical Chemical Defense (MC5) are no longer active FY23 Projects due to budget restructure. - Test and Evaluation (TE5) Project concluded in FY21. The projects in this PE support the engineering and manufacturing development phase of the Department of Defense (DoD) acquisition system and are therefore correctly placed in Budget Activity 5. Middle Tier Acquisition programs: The total cost of the Rapid Opioid Countermeasure System (ROCS) Middle Tier of Acquisition effort is $21.4 million, including RDT&E (Project MC5) and procurement of prototype units (CBDP BLIN Protection & Hazard Mitigation). The ROCS program is fully funded across the Future Years Defense Program. The total cost of the Forward Area Mobility Spray System (FAMS-S) Middle Tier of Acquisition effort is $30.5 million, including RDT&E (Project MT5) and procurement of prototype units (CBDP BLIN Protection & Hazard Mitigation). The FAMS-S program is fully funded across the Future Years Defense Program. The total cost of the Uniform Integrated Protective Ensemble Family of Systems Gloves (UIPE FOS GLOVES) Middle Tier of Acquisition effort is $38.4 million, including RDT&E (Project PT5) and procurement of prototype units (CBDP BLIN Protection & Hazard Mitigation). The UIPE FOS GLOVES program is fully funded across the Future Years Defense Program.

Open PDF

Document Details

Document Type
R2 Budgetary Justification
Publication Date
Oct 01, 2023
Source ID
0604384BP_5_0400_PB_2023
Change Summary Explanation
Funding: FY 2021 (+$8.351 Million): Below threshold reprogramming to increase advanced development programs for Joint Nuclear Biological Chemical Radiological System (JNBCRS) 1 CBRN sensor development and integration, Joint Biological Tactical Detection System (JBTDS) program test and evaluation, Man Portable Diagnostic System (MPDS) product development, and Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD) program development of specialized equipment for agent-specific threats. FY 2021 (-$11.351 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts. FY 2021 (+$36.496 Million): Joint vaccine for botulinum and plague vaccines funding restoration (+$26.996 Million), Congressional Add for decontamination technologies (+$5.000 Million), and Congressional Add for smallpox antiviral (+$4.500 Million) are all reflected in the Current President's Budget amount. FY 2023: Funding increase reflects the fact that the FY 2022 President's Budget request did not include out-year funding. Funding includes specific increases for enhanced biodefense and pandemic preparedness investments (+$60.500 Million), Departmental inflation rate adjustments (+$8.958 Million), Aerosol Vapor Chemical Agent Detector (AVCAD) program network readiness and testing (+$6.456 Million), and the Mitigate portfolio medical countermeasures efforts and Understand portfolio emerging chemical threats efforts (+$27.157 Million). Schedule: N/A Technical: N/A
Service Agency Name
Chemical and Biological Defense Program

Tags

Communities of Interest

  • Autonomy
  • Biomedical
  • Ground and Sea Platforms
  • Human Systems

DTIC Thesaurus Topics

  • Aircrafts
  • Airframes
  • Biological Products
  • Chemical Detectors
  • Chemical Warfare Agents
  • Cognitive Systems Engineering
  • Detection
  • Detectors
  • Medical Personnel
  • National Security
  • Personal Protective Equipment
  • Systems Engineering
  • Test And Evaluation
  • Unmanned Aerial Systems
  • Unmanned Aerial Vehicles
  • Warfare
  • Warning Systems

Readers

  • Critical Infrastructure Protection in CBRN and WMD Threats.
  • Military Science and Technology Research and Modernization.

Technology Areas

  • Biotechnology

Related Documents